Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adamis Pharmaceuticl (ADMP)

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,177
  • Shares Outstanding, K 61,438
  • Annual Sales, $ 15,090 K
  • Annual Income, $ -39,010 K
  • 60-Month Beta 1.36
  • Price/Sales 2.29
  • Price/Cash Flow N/A
  • Price/Book 0.79
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.84
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.11
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +61.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.48 +12.50%
on 10/16/19
0.80 -32.08%
on 09/24/19
-0.21 (-28.00%)
since 09/18/19
3-Month
0.48 +12.50%
on 10/16/19
1.28 -57.87%
on 07/19/19
-0.73 (-57.48%)
since 07/18/19
52-Week
0.48 +12.50%
on 10/16/19
3.29 -83.59%
on 02/26/19
-2.59 (-82.75%)
since 10/18/18

Most Recent Stories

More News
Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today the presentation of data pertaining to its investigational high dose naloxone product (ZIMHI) at the Institute of Human Virology...

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Announces Commercial Partnership with Emerge Health for SYMJEPI(R) in Australia and New Zealand

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has entered into an exclusive distribution and commercialization agreement with Emerge Health Pty ("Emerge") to register and commercialize...

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Announces Presentation Pertaining to Its High Dose Naloxone Product Candidate at IHV Scientific Meeting

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that Dr. Ronald Moss, Chief Medical Officer, will be presenting data on October 4, 2019, pertaining to the company's investigational high...

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today the completion of pharmacokinetic (PK) studies comparing its naloxone injection product candidate, ZIMHI(naloxone) Injection, to a generic...

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPI (epinephrine) 0.3 mg and 0.15 mg Injections.

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors.

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent...

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals (ADMP) Reports Q2 Loss, Misses Revenue Estimates

Adamis (ADMP) delivered earnings and revenue surprises of -33.33% and -1.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ADMP : 0.54 (-3.90%)
Adamis: 2Q Earnings Snapshot

SAN DIEGO (AP) _ Adamis Pharmaceuticals Corp. (ADMP) on Thursday reported a loss of $7.7 million in its second quarter.

ADMP : 0.54 (-3.90%)
Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

ADMP : 0.54 (-3.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ADMP with:

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Key Turning Points

2nd Resistance Point 0.63
1st Resistance Point 0.59
Last Price 0.54
1st Support Level 0.50
2nd Support Level 0.45

See More

52-Week High 3.29
Fibonacci 61.8% 2.22
Fibonacci 50% 1.88
Fibonacci 38.2% 1.55
Last Price 0.54
52-Week Low 0.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar